If You Invested in AI Maverick Intel Inc (AIMV)

AI Maverick Intel, Inc. (AIMV) is a technology-focused company whose business centers on the use of artificial intelligence to help other businesses acquire and engage customers. According to the company, it positions itself as a technology-driven innovator that aims to redefine how businesses approach customer acquisition, deal flow, and revenue growth through its AI Maverick platform.

Business focus and AI Maverick platform

AI Maverick Intel describes its core focus as partnering with companies to drive customer acquisition, close deals, and scale revenue using artificial intelligence. The company highlights its AI Maverick platform as the foundation of this approach, with an emphasis on intelligent growth, customer acquisition, partner-led deal flow, and revenue acceleration. This indicates that its activities are oriented around applying AI tools and methods to commercial and sales-related processes for business clients.

The company’s public communications emphasize a mission centered on using AI to support business growth. Rather than presenting itself as a general-purpose technology provider, AI Maverick Intel frames its identity around AI-enabled customer engagement and revenue-focused applications.

Corporate identity and ticker symbol

AI Maverick Intel, Inc. trades on the OTC Market under the ticker symbol AIMV. The company announced that its common shares began trading under this symbol effective October 20, 2025. This symbol change was described as part of a broader rebranding process, aligning its market identity with its operational focus on artificial intelligence and business growth solutions.

The company states that its CUSIP number and corporate structure remained unchanged in connection with the symbol change, and that shareholders were not required to take any action as a result of the transition to the AIMV ticker.

Rebranding from Bionoid Pharma, Inc.

AI Maverick Intel, Inc. reports that it previously operated under the name Bionoid Pharma, Inc. The rebranding to AI Maverick Intel, Inc. was described as reflecting a strategic focus on artificial intelligence and business-oriented technology. This shift in corporate identity is presented as part of the company’s transition toward being recognized as an AI-powered platform company rather than under its former pharmaceutical-oriented name.

The company characterizes the adoption of the AIMV ticker and the AI Maverick Intel name as milestones in completing this transition. Its public statements link the new branding directly to its emphasis on AI-driven customer acquisition and revenue scaling for partner companies.

Strategic direction

In its announcement of the AIMV trading symbol, the company referred to its intention to pursue strategic joint venture initiatives that make use of its core AI Maverick technology. These initiatives are described as being aimed at accelerating customer acquisition, expanding partner commercialization, and supporting sustainable revenue growth. This suggests that AI Maverick Intel views collaborations and partnerships as an important part of how it applies its AI platform in the market.

While detailed financial information and segment breakdowns are not provided in the available materials, the company’s own description consistently centers on artificial intelligence, customer acquisition, partner-led deal flow, and revenue acceleration as key themes in its business strategy.

Trading market

AI Maverick Intel, Inc. states that its common shares trade on the OTC Market under the symbol AIMV. The company has indicated that the change to this symbol was a market-identity adjustment associated with its rebranding, rather than a change to its underlying corporate structure or CUSIP number.

Company overview summary

In summary, AI Maverick Intel, Inc. (AIMV) presents itself as an AI-focused technology company that partners with businesses to support customer acquisition and revenue growth through its AI Maverick platform. The company’s recent history includes a rebranding from Bionoid Pharma, Inc. and the adoption of the AIMV ticker on the OTC Market, steps it describes as aligning its public identity with its AI-driven, growth-oriented mission.